Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
Jenkin D. et al, (2025), The Lancet Microbe, 101022 - 101022
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K. et al, (2025), Vaccine, 45, 126582 - 126582
Ebola disease: bridging scientific discoveries and clinical application.
Rojek A. et al, (2024), The Lancet. Infectious diseases
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.
O'Donnell KL. et al, (2024), International journal of molecular sciences, 25
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Costa Clemens SA. et al, (2024), The Lancet. Microbe
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Flaxman A. et al, (2024), PLoS pathogens, 20
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.
Bissett C. et al, (2024), NPJ vaccines, 9
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease
Drury RE. et al, (2024), Nature Communications, 15
A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
van Tol S. et al, (2024), The Journal of infectious diseases
Serological cross-reactivity between Crimean-Congo haemorrhagic fever virus and Nairobi sheep disease virus glycoprotein C
Maze EA. et al, (2024), Frontiers in Immunology, 15
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Port JR. et al, (2023), Nature communications, 14
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop G. et al, (2023), Journal of immunological methods, 523
Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.
Maze EA. et al, (2023), Viruses, 15
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Ramasamy MN. et al, (2023), The Lancet. Microbe
The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Dzau V. et al, (2023), Lancet (London, England)
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
Hornsby H. et al, (2023), Nature Communications, 14
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Barnes E. et al, (2023), Nature Medicine, 29, 1760 - 1774
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
Moore SC. et al, (2023), Med, 4, 191 - 215.e9
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Vatzia E. et al, (2023), NPJ Vaccines, 8
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.
Nyagwange J. et al, (2022), International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Shaw RH. et al, (2022), The Lancet Respiratory Medicine, 10, 1049 - 1060
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Foster WS. et al, (2022), Cell reports. Medicine
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Mentzer AJ. et al, (2022), Nature Medicine
Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda.
Atim SA. et al, (2022), The Journal of infection
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
van Doremalen N. et al, (2022), Nature Communications, 13
Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
Kearns PKA. et al, (2022)
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
McNaughton AL. et al, (2022), JCI Insight, 7
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu X. et al, (2022), The Journal of infection, 84, 795 - 813
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet (London, England), 399, 2212 - 2225
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS. et al, (2022), The Lancet. Infectious diseases
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe A. et al, (2022), JCI Insight, 7